lenalidomide has been researched along with Colorectal Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y; Wu, L; Yin, D | 1 |
| Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E | 1 |
| Chopra, R; Gandhi, AK; Jungnelius, U; Li, M; Romano, A; Schafer, PH; Shi, T; Siena, S; Tabernero, J | 1 |
| Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H | 1 |
| Falchook, G; Fu, S; Hong, DS; Janku, F; Kakadiaris, E; Kurzrock, R; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L | 1 |
| Bertino, EM; Carson, WE; Davis, M; Grever, M; McMichael, EL; Mo, X; Otterson, GA; Paul, B; Trikha, P | 1 |
| Bolton, TB; Dalgleish, AG; Galustian, C; Henry, JY; Laux, H; Liu, WM | 1 |
| Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B | 1 |
4 trial(s) available for lenalidomide and Colorectal Cancer
| Article | Year |
|---|---|
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide; Time Factors | 2013 |
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Humans; Lenalidomide; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide | 2013 |
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Response Evaluation Criteria in Solid Tumors; Thalidomide | 2016 |
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Cytokines; Female; Head and Neck Neoplasms; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Staging; Retreatment; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome | 2016 |
5 other study(ies) available for lenalidomide and Colorectal Cancer
| Article | Year |
|---|---|
Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
Topics: Apoptosis; Colorectal Neoplasms; Copper; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Prognosis; Proto-Oncogene Proteins c-akt; Tumor Microenvironment | 2022 |
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Killer Cells, Natural; Lenalidomide; Liver Neoplasms; Lung Neoplasms; Mutation; Pelvic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide | 2014 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lenalidomide; Mice; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Perfusion; Pericytes; Thalidomide; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro.
Topics: Animals; Biomarkers; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Immunologic Factors; Lenalidomide; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Quality Control; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2010 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Immunoblotting; Immunohistochemistry; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2009 |